Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report
Tóm tắt
Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents. A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We employed this combination as front-line chemoinduction therapy for a case of primary PCL. Complete remission was achieved with rapid normalization of hematologic parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates promise in the treatment of PCL.
Tài liệu tham khảo
Jimenez-Zepeda VH, Dominguez VJ: Plasma cell leukemia: a rare condition. Ann Hematol. 2006, 85 (4): 263-267. 10.1007/s00277-005-0054-4.
Sirohi B, Powles R: Multiple myeloma. Lancet. 2004, 363 (9412): 875-887. 10.1016/S0140-6736(04)15736-X.
Richardson PG, Anderson KC: Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol. 2003, 1 (10): 596-600.
Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K: Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leuk Res. 2008, 32 (7): 1153-1156. 10.1016/j.leukres.2007.11.010.
Kruger WH, Kiefer T, Schuler F, Lotze C, Busemann C, Dolken G: Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie. 2007, 30 (4): 193-195. 10.1159/000100056.
Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, Schenkein D, Pandiella A, San Miguel JF: Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer. 2005, 114 (4): 665-667. 10.1002/ijc.20793.
Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C, Park S, Choquet S, Dreyfus F, Bouscary D: Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma. 2008, 49 (10): 2012-2014. 10.1080/10428190802290660.
Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A: Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007, 109 (11): 2285-2290. 10.1002/cncr.22700.
Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, Esseltine DL, Drake M, Morris C, Cavenagh JD: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008, 141 (4): 512-516. 10.1111/j.1365-2141.2008.06997.x.
Yeung J, Chang H: Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol. 2007
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al: International uniform response criteria for multiple myeloma. Leukemia. 2006, 20 (9): 1467-1473. 10.1038/sj.leu.2404284.
Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, et al: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006, 107 (9): 3492-3494. 10.1182/blood-2005-11-4541.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006, 24 (19): 3113-3120. 10.1200/JCO.2005.04.7779.
Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, et al: Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002, 99 (10): 3735-3741. 10.1182/blood.V99.10.3735.
Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, et al: Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003, 102 (5): 1588-1594. 10.1182/blood-2002-12-3789.
Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, et al: Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003, 101 (6): 2377-2380. 10.1182/blood-2002-06-1768.
Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, et al: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007, 25 (25): 3892-3901. 10.1200/JCO.2006.10.5460.
Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, Ikeda Y: Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol. 2006, 84 (5): 406-412. 10.1532/IJH97.06142.
Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S, Lazzarino M, Corso A: Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 2007, 25 (22): 3380-3381. 10.1200/JCO.2006.10.0164.